Table 3.
Prognostic factors related to the tumor microenvironment
| Factor | Cell type | Number of patients | Significance, univariatea | Significance, multivariatea | Reference(s) |
|---|---|---|---|---|---|
| FOXP3 | Treg | 926 | + (↑FFS) | + (↑FFS) | [64] |
| 257 | + (↑DFS) | NA | [65] | ||
| 98 | + (↑FFS) | NA | [50] | ||
| 146 | - | - | [49] | ||
| FOXP3/TIA1 | Treg/CD8+ T cells | 257 | + (↓EFS, DFS) | + (↓EFS, DFS) | [65] |
| GrB | Activated; CD8+ T cells | 257 | - | - | [65] |
| 267 | + (↓OS) | + (↓OS) | [66] | ||
| 98 | - | - | [50] | ||
| 146 | - | - | [49] | ||
| TIA1 | CD8+ T cells | 257 | + (↓EFS, DFS) | NA | [65] |
| 267 | + (↓EFS, DFS, OS) | + (↓EFS, DFS, OS) | [66] | ||
| 146 | + (↓EFS) | - | [49] | ||
| 59 | + (↓PFS) | + (↓PFS) | [48] | ||
| FOXP3/GrB | Treg/activated; CD8+ T cells | 98 | + (↓FFS, OS) | + (↓FFS) | [50] |
| CD68 | TAM | 166 | + (↓PFS, DFS, DSS) | + (↓DFS) | [68] |
| 288 | + (↓EFS, OS) | + (↓OS) | [70] | ||
| FOXP3/CD68 | Treg/TAM | 122 | + (↓FFS, OS) | NA | [67] |
| CD20 | Background B cells | 166 | + (↑PFS) | - | [68] |
| 146 | +(↑EFS) | + (↑EFS) | [49] |
aThe presence (+) or absence (-) of a significant correlation (positive ↑ or negative ↓) with the study endpoints.
DSS, disease-specific survival; DFS, disease-free survival; EFS, event-free survival; FFS, failure-free survival; FOXP3, forkhead box P3; GrB, granzyme B; HLA, human leukocyte antigen; NA, not applicable; OS, overall survival; PFS, progression-free survival; TAM, tumor-associated macrophage; TIA1, cytotoxic granule-associated RNA-binding protein; Treg, regulatory T cell.